Galderma Celebrates 30 Years of Restylane
Galderma celebrates the 30th anniversary of Restylane’s launch in Europe as the first hyaluronic acid (HA) injectable.
With HA closest to the skin’s own, Restylane is designed to deliver personalized, natural-looking outcomes that meet diverse patient needs across key areas of the face, décolletage, and hands. With three decades of innovation across technology, packaging, and treatment areas, Restylane remains at the forefront of innovation, evolving from its original NASHA, technology into a comprehensive portfolio spanning three distinct technologies: NASHA HD, NASHA, and OBT. Together, these technologies offer solutions ranging from firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.
The Restylane portfolio has most recently achieved EU Medical Device Regulation certification for the products created with NASHA HD, NASHA, and OBT technologies. As one of the world’s most rigorous medical device regulatory frameworks, the certification reinforces confidence in the strong safety profile, quality standards and scientific foundation behind the portfolio.
Expanding Restylane’s versatility to support tailored aesthetic outcomes
Restylane continues to expand treatment possibilities through new technologies, indications, and devices.
A new state-of-the-art Restylane syringe was also approved in the EU, U.S. and Canada earlier this year, for use with the NASHA lidocaine Restylane products in multiple facial indications. It was designed in collaboration with over 70 aesthetics practitioners to be optimized for ergonomic functionality, ease of aspiration, and ease of operation. It has compact blister-free packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction. A survey of over 300 healthcare professionals in Brazil who had personal experience using the Restylane syringes found that 89% preferred the next-generation syringe over the standard syringe. The next-generation syringe complements Galderma’s patented SmartClick syringe for Restylane Skinboosters, which monitors each micro-dose, allowing injectors to focus on technique and placement for enhanced patient safety, precision and control.
As global demand grows for treatments that address the evolving effects on the skin of aging, menopause, and weight loss, Restylane Contour received U.S. approval in March for the correction of temple hollowing with a dual-layer patent-pending technique leveraging both needle and cannula. Temple volume loss can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance, a challenge increasingly seen in people undergoing medication-driven weight loss and experiencing age- and hormone-related changes, including menopause.
Restylane expands access to injectable aesthetics for new patient segments
Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs including medication-driven weight loss, menopause and skin quality.
Interim results from an investigator-initiated trial showed that combining Restylane Skinboosters with Sculptra – the first proven regenerative biostimulator – drove progressive improvements in hydration, skin barrier function, and overall skin quality in menopausal women. These results are reinforced by consensus guidelines concluding that Restylane Skinboosters can complement Sculptra in the décolletage for comprehensive body rejuvenation.
Additionally, Restylane also has an important role in addressing the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss. The combination of Restylane Lyft or Volyme (Contour) with Sculptra has been shown to deliver visible improvements in skin quality and significantly enhance patient satisfaction and emotional wellbeing.
Supported by 30 years of innovation and more than 77 million treatments administered worldwide, Restylane has helped define the HA injectable category and continues to shape the future of aesthetic medicine. With more than 80 clinical trials, 180 publications and around 407,000 patients evaluated for safety, its legacy is built on extensive scientific evidence and clinical experience. These milestones demonstrate Galderma’s ongoing commitment to using its unique dermatology expertise and strong portfolio to meet the needs of patients and healthcare professionals today and tomorrow.
About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results. Its HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose. Powered by NASHA HD, NASHA, and OBT technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow. Trusted for almost three decades, its HA gels work in sync with your skin for 100% natural-looking results. Approved indications vary by market.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. They deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because they understand that the skin we are in shapes our lives, Galderma is advancing dermatology for every skin story. For more information: www.galderma.com.
